马来酸罗格列酮

参考文献

1.葛兰素史克。阿凡迪亚（马来酸瑞格列酮）片规定信息。北卡罗莱纳州三角研究园； 2014年5月。

2. Young PW，Buckle DR，Cantello BCC等。使用针对过氧化物酶体增殖物激活受体γ的放射性碘配体，鉴定啮齿动物和人脂肪细胞中胰岛素增敏剂罗格列酮（BRL-49653）的高亲和力结合位点。药理学疗法杂志。 1998年； 284：751-9。 http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus

3.Martin G，Schoonjans K，Lefebvre AM等。 PPAR对脂肪酸转运蛋白和酰基辅酶A合成酶基因表达的协调调控？和PPARγ激活剂。生物化学杂志。 1997; 272：28210-7。 http://www.ncbi.nlm.nih.gov/pubmed/9353271?dopt=AbstractPlus

4. Adams M，Montague CT，Prins JB等。过氧化物酶体增殖物激活的受体γ的激活剂对人类前脂肪细胞的分化具有储库特异性作用。 J临床投资。 1997; 100：3149-53。 http://www.ncbi.nlm.nih.gov/pubmed/9399962?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=508528&blobtype=pdf

5.帕克·戴维斯。雷祖林（曲格列酮）片规定信息。新泽西州莫里斯平原（Morris Plains）； 1998年7月

6.Cantello BCC，Cawthrone MA，Cottam GP等。 [[[-（杂环基氨基）烷氧基]苄基] -2,4-噻唑烷二酮类作为有效的降血糖药。医学化学杂志。 1994年； 37：3977-85。 http://www.ncbi.nlm.nih.gov/pubmed/7966158?dopt=AbstractPlus

7. Lohray BB，Bhushan V和Rao BP。新型的正常血糖和降血脂药。 1. Drug MetabolRev 。 1998年； 41：1619-30，

9. Parks DJ，汤金森NCO，维伦纽夫MS等。罗格列酮对映异构体在PPARγ上的差异活性。 Bioorg Med Chem 。 1998年； 8：3657-8。

10. Oakes ND，Kennedy CJ，Jenkins AB等。一种新的抗糖尿病药BRL 49653可减少脂质的利用，并改善大鼠的胰岛素作用和糖调节。糖尿病。 1994年； 43：1203-10。 http://www.ncbi.nlm.nih.gov/pubmed/7926289?dopt=AbstractPlus

11. Young PW，Cawthrone MA，Coyle PJ等。重复使用BRL 49653对肥胖小鼠进行治疗，BRL 49653是一种在白色脂肪细胞中的新型有效胰岛素增敏剂：与增加的胰岛素结合和通过光亲和性标记测量的细胞表面GLUT4相关。糖尿病。 1995; 44：1087-92。 http://www.ncbi.nlm.nih.gov/pubmed/7657033?dopt=AbstractPlus

13. Oakes ND，Camilleri S，Furler SM等。胰岛素增敏剂BRL 49653可降低大鼠体内的全身脂肪酸供应和利用以及组织脂质的利用率。代谢。 1997; 46：935-42。 http://www.ncbi.nlm.nih.gov/pubmed/9258278?dopt=AbstractPlus

14. Souza AC，Yamamoto MT，Francisosa MD等。 BRL 49653阻断肿瘤坏死因子-α的脂解作用。糖尿病。 1998年； 47：691-5。 http://www.ncbi.nlm.nih.gov/pubmed/9568706?dopt=AbstractPlus

16. Berger J，Bailey P，Biswas C等。噻唑烷二酮在过氧化物酶体增殖物激活的受体-γ中产生构象变化：结合和激活与db / db小鼠的抗糖尿病作用相关。内分泌学。 1996; 137：4189-95。 http://www.ncbi.nlm.nih.gov/pubmed/8828476?dopt=AbstractPlus

20. Saltiel AR，Olefsky JM。噻唑烷二酮类药物可治疗胰岛素抵抗和II型糖尿病。糖尿病。 1996; 45：1661-9。 http://www.ncbi.nlm.nih.gov/pubmed/8922349?dopt=AbstractPlus

25.释放的MI，Allen A，Jorkasky DK等。食物对罗格列酮的全身暴露不会改变。 Eur J临床Pharmacol 。 1999年； 55：53-6。 http://www.ncbi.nlm.nih.gov/pubmed/10206085?dopt=AbstractPlus

30. Barman Balfour JA，Plosker GL。罗格列酮。毒品。 1999年； 57：921-30。 http://www.ncbi.nlm.nih.gov/pubmed/10400405?dopt=AbstractPlus

101.Parke-Davis。雷祖林（曲格列酮）片规定信息。新泽西州莫里斯平原（Morris Plains）； 1999年6月

102.西格蒙德WR II。亲爱的健康专业人士，有关Rezulin重要处方信息的信。新泽西州莫里斯平原（Morris Plains）：帕克·戴维斯（Parke Davis）。 （未注明日期）

103. Anon。 Rezulin的新标签和用途更改。 FDA谈话纸。马里兰州罗克维尔：食品药品监督管理局； 1999年6月16日

104.宾夕法尼亚州费城SmithKline Beecham Pharmaceuticals：个人交流。

105.Gomis R，Jones NP，Vallance SE等。当与磺酰脲类药物联合用于2型糖尿病（T2D）时，小剂量罗格列酮（RSG）可提供附加的血糖控制。糖尿病。 1999年； 48（增补1）：A63。

106. Wolffenbuttel BHR，Gomist R，Squatrito S等。在磺脲类药物治疗中加入小剂量罗格列酮可改善2型糖尿病患者的血糖控制。糖尿病医学。 2000; 17：40-7。 http://www.ncbi.nlm.nih.gov/pubmed/10691158?dopt=AbstractPlus

107.美国糖尿病协会。儿童和青少年的2型糖尿病。小儿科。 2000; 105：671-80。 http://www.ncbi.nlm.nih.gov/pubmed/10699131?dopt=AbstractPlus

108.国家临床卓越研究所，国家卫生局。罗格列酮治疗2型糖尿病的指南。英国伦敦。美国国家临床卓越研究所，2000年8月，技术鉴定指南，第9号。

109. Lebovitz HE，Kreider M，密苏里州释放。在临床试验中评估2型糖尿病患者的肝功能：罗格列酮不会引起肝功能障碍的证据。糖尿病护理。 2002年； 25：815-21。

110.葛兰素史克。阿万达梅特（马来酸瑞格列酮和盐酸二甲双胍）片开处方信息。北卡罗莱纳州三角研究园； 2014年5月。

111.百时美施贵宝公司。血糖(glyburide and metformin hydrochloride) tablets prescribing information.新泽西州普林斯顿； 2013 Oct.

112. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.贾玛2000; 283:1695-702. http://www.ncbi.nlm.nih.gov/pubmed/10755495?dopt=AbstractPlus

113. GlaxoSmithKline, Philadelphia, PA: Personal communication.

114. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care . 2007; 30(Suppl 1):S4-41.

115. Novo Nordisk. Prandin (repaglinide) tablets prescribing information.新泽西州普林斯顿； 2011 Sept.

116. Takeda Pharmaceuticals America. Actos (pioglitazone hydrochloride) tablets prescribing information. Deerfield, IL; 2007 Aug.

117. Nesto RW, Bell D, Bonow RO et al for the American Heart Association and American Diabetes Association. AHA/ADA consensus statement: thiazolidinedione use, fluid retention, and congestive heart failure.流通量。 2003; 108:2941-48. http://www.ncbi.nlm.nih.gov/pubmed/14662691?dopt=AbstractPlus

118. GlaxoSmithKline.阿凡达丽(rosiglitazone maleate and glimepiride) tablets prescribing information.北卡罗莱纳州三角研究园； 2014年5月。

119. Cobitz AR. Dear healthcare provider letter regarding diabetic macular edema associated with rosiglitazone-containing preparations (Avandia , Avandamet , Avandaryl ）。 Research Triangle Park, NC: GlaxoSmithKline; 2005 Dec.

120. Herman WH, Dirani RG, Horblyuk R et al. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early SULfonylurea Titration (RESULT) study. Am J Managed Care . 2005; 11:273-8.

121. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care . 2006年； 29:1963-72. http://www.ncbi.nlm.nih.gov/pubmed/16873813?dopt=AbstractPlus

122. Canadian Diabetes Association, Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes . 2003; 27 (Suppl 2):S1-152.

123. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.柳叶刀。 2006年； 368:1096-105.

124. Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same?柳叶刀。 2006年； 368:1218-9.

125. Cobitz AR. Dear health care provider letter: Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus. Philadelphia, PA: GlaxoSmithKline; 2007 Feb.

126. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.新英格兰医学杂志2006年； 355:2427-43. http://www.ncbi.nlm.nih.gov/pubmed/17145742?dopt=AbstractPlus

127. Spanheimer R. Dear healthcare provider letter: Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus. Deerfield, IL: Takeda Pharmaceuticals North America, Inc.; 2007 Mar.

128.食品和药物管理局。 Information for healthcare professionals: rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). Rockville, MD: Food and Drug Administration; 2007 Aug 14. Available from FDA website. Accessed 2007 Sep 21. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143349.htm

129.食品药品监督管理局。 FDA issues safety alert on Avandia.马里兰州罗克维尔; 2007 May 21. FDA News release No. P07-88.可从FDA网站获得。 Accessed 2007 Sep 21. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108917.htm

130. Nissen SE, Wolski K. Effect of rosigltiazone on the risk of myocardial infarction and death from cardiovascular causes.新英格兰医学杂志2007; 356:2457-71. http://www.ncbi.nlm.nih.gov/pubmed/17517853?dopt=AbstractPlus

131. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis.新英格兰医学杂志2007; 357:28-38. http://www.ncbi.nlm.nih.gov/pubmed/17551159?dopt=AbstractPlus

132. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction.新英格兰医学杂志2007; 357:67-9. http://www.ncbi.nlm.nih.gov/pubmed/17551162?dopt=AbstractPlus

133. Drazen JM, Morrissey S, Curfman GD. Rosilgitazone — continued uncertaintly about safety.新英格兰医学杂志2007; 357:63-4. http://www.ncbi.nlm.nih.gov/pubmed/17551160?dopt=AbstractPlus

134. Nathan DM. Rosiglitazone and cardiotoxicity — weighing the evidence.新英格兰医学杂志2007; 357:64-6. http://www.ncbi.nlm.nih.gov/pubmed/17551161?dopt=AbstractPlus

135. Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk.马里兰州罗克维尔; 2007 Aug 14. FDA News release.可从FDA网站获得。 Accessed 2007 Sep 21. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108966.htm

136. GlaxoSmithKline. Avandamet (rosiglitazone maleate and metformin hydrochloride) tablets medication guide.北卡罗莱纳州三角研究园； 2011 May.

137. GlaxoSmithKline.阿凡达丽(rosiglitazone maleate and glimepiride) tablets medication guide.北卡罗莱纳州三角研究园； 2011 May.

138. Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care . 2007; 30:2773-8 http://www.ncbi.nlm.nih.gov/pubmed/17666462?dopt=AbstractPlus

139. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults.临床内分泌代谢。 2006年； 91:3349-54. http://www.ncbi.nlm.nih.gov/pubmed/16608888?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1563497&blobtype=pdf

141. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.柳叶刀。 2005; 366:1279-89. http://www.ncbi.nlm.nih.gov/pubmed/16214598?dopt=AbstractPlus

142. Dargie HJ, Hildebrandt PR, Riegger GAJ et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol . 2007; 49:1696-704. http://www.ncbi.nlm.nih.gov/pubmed/17448371?dopt=AbstractPlus

143. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.柳叶刀。 2007; 370:1129-36. http://www.ncbi.nlm.nih.gov/pubmed/17905165?dopt=AbstractPlus

144. GlaxoSmithKline. Study no. ZM2005/00181/01: Avandia cardiovascular event monitoring project.北卡罗莱纳州三角研究园； 2006 Oct 27. From GlaxoSmithKline website. http://www.gsk-clinicalstudyregister.com

145. Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk.大实习医生。 2008; 168:820-5. http://www.ncbi.nlm.nih.gov/pubmed/18443256?dopt=AbstractPlus

146. GlaxoSmithKline. Avandia (rosiglitazone maleate) tablets medication guide.北卡罗莱纳州三角研究园； 2014年5月。

147. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care . 2008; 31:845-51. http://www.ncbi.nlm.nih.gov/pubmed/18223031?dopt=AbstractPlus

148. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care . 2008; 31:173-5. http://www.ncbi.nlm.nih.gov/pubmed/18165348?dopt=AbstractPlus

149. American Heart Association. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Dallas, TX; 1994. Available from AHA website. Accessed 2008 Apr.10. http://www.americanheart.org/presenter.jhtml?identifier=1712

150. Bristow MR. Management of heart failure. In: Braunwald E, Zipes DP, Libby P eds. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia: WB Saunders Company; 2001:640-1.

151. Nathan DM, Holman RR, Buse JB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care . 2009; 32:192-203.

152. Strowig S, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care . 2004; 27:1577-83. http://www.ncbi.nlm.nih.gov/pubmed/15220231?dopt=AbstractPlus

154. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes?新英格兰医学杂志2006年； 355:2477-80.社论。

155. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone.荟萃分析。贾玛2007 298:1189-95.

156. Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA. 2007; 298:1180-8.

157. American Diabetes Association. Summary of revisions for the 2009 clincal practice recommendations. Diabetes Care . 2009; 32:S3-S5. http://www.ncbi.nlm.nih.gov/pubmed/19118287?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2613585&blobtype=pdf

158. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care . 2009; 32 Suppl 1:S62-7.

159. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.安实习生。 1996;124(1 Part 2):104-9.

160. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus.安实习生。 1996; 124:97-103. http://www.ncbi.nlm.nih.gov/pubmed/8554221?dopt=AbstractPlus

161. Bailey C, Turner R. Metformin.新英格兰医学杂志1996; 334:374-9. http://www.ncbi.nlm.nih.gov/pubmed/8538710?dopt=AbstractPlus

162. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care . 1994年； 17:1542-4. http://www.ncbi.nlm.nih.gov/pubmed/7882832?dopt=AbstractPlus

163. Zimmerman BR. Preventing long term complications: implications for combination therapy with acarbose.毒品。 1992年； 44:54-9. http://www.ncbi.nlm.nih.gov/pubmed/1280578?dopt=AbstractPlus

164. Klein R, Klein BEK, Moss SE et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy.贾玛1988年； 260:2864-71. http://www.ncbi.nlm.nih.gov/pubmed/3184351?dopt=AbstractPlus

165. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin- dependent diabetes mellitus; a randomized prospective 6-year study. Diabetes Res Clin Pract . 1995; 28:103-17. http://www.ncbi.nlm.nih.gov/pubmed/7587918?dopt=AbstractPlus

166. Defronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus.美国医学杂志1983年； 74(Suppl 1A):52-81. http://www.ncbi.nlm.nih.gov/pubmed/6337486?dopt=AbstractPlus

167. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies.安实习生。 1996;124(1 Part 2):127-30.

168. Scheen AJ, Letiexhe MR, Lefèbvre PJ. Effects of metformin in obese patients with impaired glucose tolerance. Diabetes/Metabolism Reviews . 1995; 11:S69-80.

169. Williams G. Management of non-insulin-dependent diabetes mellitus.柳叶刀。 1994年； 95-100.

170. DeFronzo RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes . 1988年； 37:667-87. http://www.ncbi.nlm.nih.gov/pubmed/3289989?dopt=AbstractPlus

171. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance.新英格兰医学杂志1996; 334:777-83. http://www.ncbi.nlm.nih.gov/pubmed/8592553?dopt=AbstractPlus

172. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.毒品。 1995; 49:721-49. http://www.ncbi.nlm.nih.gov/pubmed/7601013?dopt=AbstractPlus

173. Gerich JE. Oral hypoglycemic agents.新英格兰医学杂志1989年； 321:1231-45. http://www.ncbi.nlm.nih.gov/pubmed/2677730?dopt=AbstractPlus

174. Bristol-Myers Squibb, Princeton, NJ: personal communication.

175. Giugliano D, Quatraro A, Consoli G et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J临床Pharmacol 。 1993年； 44:107-12. http://www.ncbi.nlm.nih.gov/pubmed/8453955?dopt=AbstractPlus

176. Hother-Nielsen O, Schmitz O, Andersen PH et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol . 1989年； 120:257-65. http://www.ncbi.nlm.nih.gov/pubmed/2648723?dopt=AbstractPlus

177. Swislocki A. Insulin resistance and hypertension. Am J Med Sci . 1990年； 300:104-15. http://www.ncbi.nlm.nih.gov/pubmed/2206054?dopt=AbstractPlus

178. DeFronzo RA, Bonadonna RC, Ferannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care . 1992年； 15:318-68. http://www.ncbi.nlm.nih.gov/pubmed/1532777?dopt=AbstractPlus

200. Klein S, Allison DB, Heymsfield SB et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007; 30:1647-52.

201. American Diabetes Association. Type 2 diabetes in children and adolescents.小儿科。 2000; 105:671-80. http://www.ncbi.nlm.nih.gov/pubmed/10699131?dopt=AbstractPlus

202. American Diabetes Association. Summary of revisions for the 2009 clinical practice recommendations. Diabetes Care . 2009; 32:S3-5. http://www.ncbi.nlm.nih.gov/pubmed/19118287?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2613585&blobtype=pdf

203. DluhyRG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials.新英格兰医学杂志2008; 358:2630-33.社论。

204. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.英国医学杂志2000; 321:405-12. http://www.ncbi.nlm.nih.gov/pubmed/10938048?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=27454&blobtype=pdf

205. US Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia.马里兰州罗克维尔; 2010 Sep 23. News release from FDA web site. Accessed 2010 Nov 15. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975

206. Woodcock J (US Food and Drug Administration). Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl).马里兰州罗克维尔; Available at FDA website. Accessed 2010 Nov 15. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf

207. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the US Food and Drug Administration.新英格兰医学杂志2010; 363;1489-91. Commentary. http://www.ncbi.nlm.nih.gov/pubmed/20942663?dopt=AbstractPlus

208. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.马里兰州罗克维尔; 2008 Dec. Available at FDA website. Accessed 2010 Nov 15. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf

209. Jenkins JK (US Food and Drug Administration). Recommendations for regulatory actions – rosiglitazone.马里兰州罗克维尔; 2010 Sep 2. Available at FDA website. Accessed 2010 Nov 15. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226236.pdf

210. Kaul S, Bolger AF, Herrington et al. Thiazolidinedione drugs and cardiovascular risks. A science advisory from the American Heart Association and American College of Cardiology Foundation.流通量。 2010;121:1868-77.

211. Woodcock J (US Food and Drug Administration). Safety labeling change, REMS, and PMR notification for rosiglitazone.马里兰州罗克维尔; 2010 Sep 23. Available at FDA website. Accessed 2010 Nov 15. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM227950.pdf

212. Nissen SE, Wolski K. Rosiglitazone revisited—an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.大实习医生。 2010; 170:1191-1201. http://www.ncbi.nlm.nih.gov/pubmed/20656674?dopt=AbstractPlus

213. Home PD, Pocock SJ, Beck-Nielsen H et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination t